info icon

This is a non-core endpoint: only basic statistics are computed.

See its core counterpart C3_KAPOSI_SARCOMA_EXALLC for full statistics.

Kaposi sarcoma

C3_KAPOSI_SARCOMA

Kaposi's sarcoma: A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).

Endpoint definition

FinnGen phenotype data

429209 individuals

diagram downward connector

Apply sex-specific rule None

429209

diagram downward connector

Check conditions None

429209

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 C46
Cause of death: ICD-10 C46

2 out of 7 registries used, show all original rules.

46

diagram downward connector

Check minimum number of events None

46

diagram downward connector

Include endpoints None

46

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

44

diagram downward connector
C3_KAPOSI_SARCOMA

Control definitions

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy 3
First used in FinnGen datafreeze DF4
Parent code in ICD-10 C45-C49
Name in latin Sarcoma Kaposi

Summary Statistics

Key figures

All Female Male
Number of individuals 44 10 34
Unadjusted prevalence (%) 0.01 0.00 0.02
Mean age at first event (years) 67.19 64.81 67.89

Mortality

Not a core endpoint, no data to show.

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Not a core endpoint, no data to show.

Correlations

Index endpoint: C3_KAPOSI_SARCOMA – Kaposi sarcoma
GWS hits:

Survival analyses between endpoints

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Kaposi sarcoma

Endpoint not on priority list, no data to show.